Abstract
Analytical view of the human organism, its physiology and pathology, treatment methods, formed under the influence of many centuries of observing the progress of the disease, when there was not this or that individual symptoms and groups related by birth, with common features and parallel flow of symptoms, under the influence of treatment and its effects have been studied as weight, texture, color, damaged organs, the link between a specific and complex pathology of affected organs and tissues. Thus was formed syndromal diagnosis of multiple sclerosis, where each syndrome reflects the general, substantiality and local disturbances, had characteristic diagnostic features. On the basis of this multi-faceted study of the patient was placed syndromic diagnosis and the appropriate treatment approach, aimed at restoring the overall balance of the body's defenses.
References
2. Committee on Multiple Sclerosis: Current status and Strategies for the future//Janet E. Joy and Richard B. Johnston, Jr., Editors.- Washington:National Academy Press, 2001.- 457 р.
3. Handbook of multiple sclerosis //Tird edition, edited by S.D. Cook.- Basel: Marcel Dekker AG, 2001.- 702 p.
4. Johnson KP. The historical development of interferons as multiple sclerosis therapies// J Mol Med.- 1997;75(2):89-94.
5. Miller H.G, Newell D.J, Ridley A. Multiple sclerosis: trials of maintenance treatment with prednisolone and soluble aspirin// Lancet. 1961;1:127-129.
6. Murray T. J. Multiple sclerosis: the history of a disease// Murray T. J.- New York:Demos, 2005.- 248 c.
7. Rudick RA, Cookfair DL. Conduct of a clinical trial in multiple sclerosis. In: Multiple Sclerosis: Clinical and Pathogenic Basis// Cedric S, Raine HF, McFarlane WW, eds. Tourtellotte. London: Chapman and Hall- 1997:341-353.
8. Vanuakes EC, Pineda AA, Weinshenker BG. Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis// J Clin Apheresis.- 1995;10:163-170.
9. Weinshenker BG. Therapeutic plasma exchange. In: Rudick RA, Goodkin DG, eds. //Multiple Sclerosis Therapeutics. London: Martin Dunitz.- 1999:323-333.